Malattie respiratorie severe

Severe Respiratory Diseases

Severe respiratory diseases: from Cystic Fibrosis to bronchiectases

Around 100,000 people worldwide suffer from Cystic Fibrosis, the most common severe genetic disease. This multi-organ disease mainly affects the lungs, which are hit by chronic infections and inflammations that cause their progressive deterioration. COPD (Chronic Obstructive Pulmonary Disease) is another chronic and progressive respiratory disorder, the main cause of which is exposure (active or passive) to tobacco smoke.

*Sources: ECFS Patient Registry, Report 2015; World Health Organization

200

New cases of Cystic Fibrosis every year in Italy

Source: ECFS Patient Registry, Report 2015
48%

Cases of Cystic Fibrosis affecting children in Europe

Source: ECFS Patient Registry, Report 2015
250 Mil

Cases of Chronic Obstructive Pulmonary Disease (COPD) worldwide in 2016

Source: World Health Organization

We want to develop treatments that play a key role in treating Cystic Fibrosis, as well as in managing severe respiratory diseases

Malattie respiratorie severe

Zambon has initiated two pivotal trials for patients suffering from bronchiectases 

PIPELINE

Preclinical
Phase 1
Phase 2
Phase 3
Phase 4
Phase 3
US: CMS & I-Neb for Non-Cystic Fibrosis Bronchiectasis (NCFB)
Phase 3
EU: CMS & I-Neb for Non-Cystic Fibrosis Bronchiectasis (NCFB)
Phase 2
US: CMS & I-Neb Cystic Fibrosis (CF)

OUR DIRECT PRESENCE

Visita il sito di I-Neb

I-Neb: an innovative inhaler for treating bronchial infections 

I-Neb is an innovative medical device developed by Zambon in partnership with Philips.

Thanks to this device, Zambon continues to support patients and health care professionals in ensuring compliance with treatment.

Alongside research into new innovative drugs, support for patients plays a key role with regard to rare diseases such as Cystic Fibrosis. 

contact
PARTNERNING OPPORTUNITIES
Tony Maggi
Head of Business Development
+39 02 66524378